Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline For Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

robot
Abstract generation in progress

Kahn Swick & Foti, LLC (KSF) has notified investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) about a class action securities lawsuit. The lawsuit seeks to recover losses for investors who allegedly suffered damages due to securities fraud between August 3, 2023, and December 26, 2025. The deadline for investors to apply to be lead plaintiff in the lawsuit is April 6, 2026, following a significant drop in Ultragenyx’s stock price after the announcement of failed Phase 3 clinical trials for its drug setrusumab.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin